AffiliationLiverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool Heart & Chest Hospital, Liverpool,
MetadataShow full item record
AbstractAtrial fibrillation (AF) is the most common cardiac arrhythmia and a significant cause of cardiovascular morbidity and mortality worldwide (1). Ibrutinib is a covalent irreversible inhibitor of Bruton’s tyrosine kinase (BTK) used in the treatment of B-cell cancers such as chronic lymphocytic leukemia and mantle cell lymphoma. It is estimated that up to 16% of patients develop ibrutinibinduced AF, which can be a therapy-limiting side effect. The mechanisms are not clear but may relate to direct inhibition of BTK, which is expressed in cardiac tissue (2). In this primer, we use a clinical case of a patient with chronic lymphocytic leukemia to demonstrate the challenges and management considerations of AF secondary to ibrutinib.
CitationEssa H, Lodhi T, Dobson R, Wright D, Lip GYH. How to Manage Atrial Fibrillation Secondary to Ibrutinib. JACC: CardioOncology. 2021 Mar;3(1):140–4.